The latest price of Ryeqo in 2024 announced by the whole network

Introduction: Ryeqo (relugolix/estradiol/norethindrone acetate) is an oral hormonal drug containing 3 ingredients, which can be used to relieve excessive menstrual flow caused by uterine fibroids. The first ingredient in Ryeqo is GnRHa relugolix, which inhibits the release of pituitary stimulating hormone, thereby reducing the production of estrogen and progesterone by the ovaries. The second ingredient is estrogen, which can relieve menopausal symptoms and prevent osteoporosis. The third ingredient is progesterone, which protects the lining of the uterus.

The latest price of Ryeqo in 2024 announced on the entire network

Currently, it is understood that the price of a box of 40mg*100 tablets is about 8000$-8600$, and patients need to pay for it at their own expense. It will be affected by many factors, such as market demand, pharmaceutical costs, exchange rate changes, etc., so the actual price may change.

Patients are advised to contact relevant medical institutions or drug suppliers directly before purchasing to obtain the latest price information. At the same time, because Ryeqo has not yet been launched in China, patients need to purchase it through overseas medical service institutions or go abroad to purchase it in person.

Efficacy of Ryeqo in the treatment of endometriosis

Two studies have shown that Ryeqo is effective in treating the symptoms of endometriosis. The subjects were women of childbearing age (18-50 years old) with moderate to severe pain symptoms. In both studies, approximately 630 patients received Ryeqo or placebo for 24 weeks.

In the first study, 75% of women who took Ryeqo reported less menstrual pain, compared with 27% of women who took a placebo. The proportion of women who took Ryeqo also experienced less menstrual pain (59%) than those who took placebo (40%).

In the second study, 75% of patients who took Ryeqo experienced less menstrual pain, compared with 31% of patients who took a placebo. In addition, a higher proportion of women taking Ryeqo (66%) experienced a reduction in extramenstrual pain than those taking a placebo (43%).

Ryeqo’s use in special populations

1. Patients with renal insufficiency: Patients with mild, moderate or severe renal insufficiency do not need to adjust the dosage of Ryeqo.

2. Patients with hepatic insufficiency: Patients with mild or moderate hepatic insufficiency do not need to adjust the dose of Ryeqo. However, for patients with severe hepatic insufficiency, Ryeqo is contraindicated if the liver function values ​​do not return to normal.

3. Children: There is currently no data on the use of Ryeqo in children under 18 years old, so it is not recommended for children.

Ryeqo is contraindicated in patients with a history of thromboembolic disease, osteoporosis*, and patients with malignant tumors.